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Primary pulmonary hypertension (PPH) is a rare condition
characterized by neointimal vascular occlusion of small
pulmonary arteries that leads to circulatory failure and death
(1–3). Severe pulmonary arterial hypertension with identical
pathologic obliteration of the pulmonary vasculature is also
seen in patients with familial pulmonary hypertension,
human immunodeficiency virus, liver cirrhosis, scleroderma
syndrome, systemic lupus erythematosis, and in patients
who take diet pills (1,4,5). At present there is no medical
cure for pulmonary hypertension, and, untreated, the disease
is progressive, with a median survival of three years after
diagnosis (6).
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Pathologic pulmonary hypertension is associated with
excessive expression of vasoconstrictors such as endothelin
and thromboxane (7) and with deficiency of vasodilators
such as prostacyclin (2,8). The expression of endothelial
nitric oxide synthase in patients with pulmonary hyperten-
sion was reported by one group to be decreased (9); other
investigators reported no decrease or an increase (10–12).
The imbalance of vasoconstrictors and vasodilators in pul-
monary hypertension provided the rationale, over the past
two decades, for therapies principally directed at augment-
ing pulmonary arterial vasodilation. Such agents include
calcium channel blockers, prostacyclin and its analogs (in-
travenous epoprostenol (13), subcutaneous treprostinil (14),
inhaled iloprost (15), oral beraprost (16), endothelin recep-
tor antagonists (17), and phosphodiesterase inhibitors (sil-
denafil) (18). Approximately 15% of patients identified as
those with an early vasodilator response have a significant
long-term therapeutic response to calcium channel blocking
agents (19). The mainstay of treatment for most patients
with advanced PPH who lack an early vasodilator response
is long-term administration of prostacyclin (13). Because
PPH is an aggressive disease with a poor short-term survival
rate, many studies of new therapies in PPH involve treat-
ment periods that are three months or shorter in duration
(13–17).
Prostacyclin is a potent arterial vasodilator with anti-
thrombotic and anti-proliferative effects (20). Prostacyclin is
synthesized in endothelial cells and acts through G-protein-
coupled prostacyclin receptors on the surface of vascular
smooth muscle cells to elevate intracellular cyclic adenosine
monophosphate and produce vascular relaxation. Prostacy-
clin and its analogs suppress proliferation of vascular smooth
muscle cells in vitro, with treprostinil (UT-15) demonstrat-
ing 10-fold greater potency than beraprost (21). Continuous
administration of intravenous prostacyclin (epoprostenol)
has been associated with improved survival, exercise toler-
ance, and heart failure class (13,22–26). Most patients
initiated on epoprostenol infusion do not demonstrate an
early vasodilator response, yet achieve clinical benefits after
several months of continuous infusion. These benefits are
thought to arise from anti-proliferative effects and beneficial
pulmonary vascular remodeling in response to epoprostenol.
Although some benefits of epoprostenol treatment accrue
over time, sustained reversal of established disease has been
difficult to demonstrate. Sitbon et al. (24) showed, in 107
patients treated with epoprostenol infusion, that the major
improvement in hemodynamics was achieved in the first
three months, without further improvement detected at 12
months. Continuous intravenous administration of epopro-
stenol through an indwelling central venous catheter carries
a risk of bacteremia (13,25), and the therapy is inconvenient
for patient use. An oral medication that is effective therapy
for PPH would represent a significant advance.
Contributions of the current article. In this issue of the
Journal, Barst et al. (27) present data on the effects of the
oral prostacyclin analog beraprost sodium in patients with
PPH. This study, performed over 12 months, represents the
longest controlled clinical trial performed in PPH. Bera-
prost therapy was administered in escalating doses and,
compared with placebo, was associated with benefits. Bera-
prost produced a significant improvement over placebo in
the primary outcome measure (disease progression) only at
the six-month time point. The secondary outcome measure
was exercise endurance, and compared with placebo, bera-
prost significantly improved the 6-min walk distance at 3
and 6 months; however, there was no statistical difference at
9 or 12 months. The results suggest that studies that are
longer than three months might be useful in assessing the
efficacy of new therapies for pulmonary hypertension, be-
cause benefits that are apparent at three months might not
be apparent with longer duration of therapy. The result is
important because several therapies have been accepted into
common practice based on their effects on exercise tolerance
over periods of three months or less (14–17).
There are several possible explanations why benefits were
demonstrable at 3 and 6 months but not at 9 and 12
months. First, this discrepancy could be attributed to a type
2 error (failing to reject the null hypothesis when it is false),
in which the study design (in particular, the population size
and heterogeneity) fails to demonstrate a statistically signif-
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icant difference when a true difference does exist (28).
Factors that influence whether a statistically significant
difference between therapies is reached include the number
of subjects in each treatment group (in this study, a smaller
number reached 12 months due to premature discontinua-
tion of the study by the sponsor), the variability in the
outcome measure (in general, biologic measures are less
reproducible over time) (29), and the magnitude of the
treatment effect related to the standard deviation of each
group (30). The notion that a difference between beraprost
and placebo exists but did not reach statistical significance at
both nine and 12 months is supported by the trend in this
study toward improvement in 6-min walk distance that was
still evident at both nine and 12 months but did not reach
statistical significance.
The possibility also remains that beraprost is no different
from placebo after nine months of therapy. There are at
least two distinct (but not mutually exclusive) biologic
explanations for such a result. First, there might be a loss of
drug efficacy due to altered natural history of disease. Newly
diagnosed subjects might respond well to therapy, but
subjects with more severe or a longer duration of disease
may not. This concept is supported by the survival advan-
tage of subjects with New York Heart Association (NYHA)
class I and II severity of disease, compared with subjects
with NYHA class III and IV disease, particularly when
treated with intravenous epoprostenol (22). The second
possible explanation is drug tolerance (in which repeated
administration of a drug after a period of time leads to a
decrease in its effectiveness) or a failure to increase the drug
dosage to reach therapeutic efficacy. The latter may be an
important possibility in this study because patients who take
intravenous prostacyclin generally increase the administered
dosage to achieve therapeutic efficacy (25). The question
remains whether therapies that have a proven benefit after
three months and are currently widely prescribed should be
re-evaluated for efficacy during long-term (6 months)
administration. Currently, little is known about the long-
term effects of endothelin antagonists, subcutaneous pros-
tacyclin analogs, or sildenafil on exercise tolerance or sur-
vival.
Genetic insights and the potential role for anti-prolif-
erative therapies in PPH. The recognition of familial
PPH, with clinical presentation and pathology identical to
sporadic PPH, and autosomal dominant inheritance, led to
the breakthrough identification of a genetic basis for hyper-
tensive pulmonary vascular disease (31–33). Mutations in
the coding region of the bone morphogenetic protein
receptor type II (BMPR2) occur in 50% of patients with
familial PPH and 26% of patients with sporadic PPH. Bone
morphogenetic proteins and their receptors are important
for development and regulation of the cardiovascular sys-
tem. The BMPR2 gene encodes a transmembrane receptor
with protein kinase activity, which is a member of the
transforming growth factor receptor superfamily. The
BMPR2 protein serves to transmit anti-proliferative signals
to vascular endothelial and smooth muscle cells. Mutations
in one allele of BMPR2, causing haploinsufficiency and
defective anti-proliferative signaling, appear to predispose
individuals to development of pulmonary vascular disease
(34). Atkinson et al. (35) demonstrated a reduced expression
of BMPR2 protein in pulmonary vessels of patients with
PPH, even in those PPH patients with no detectable
mutation in BMPR2 coding sequences. Together, these
results strongly support a role for the BMPR2 signaling
pathway and abnormal regulation of vascular proliferation in
the development of PPH and other pulmonary vascular
diseases, such as pulmonary veno-occlusive disease (36).
Newman et al. (34) analyzed a large kindred and determined
that PPH developed only in 15% of individuals who carry a
mutation in BMPR2, implicating other factors, likely envi-
ronmental, immune, or hormonal factors, as necessary for
development of PPH (37).
The new insight that significant numbers of PPH pa-
tients carry a genetic predisposition to vascular proliferation
correlates with morphologic characterizations demonstrat-
ing inappropriate neointimal proliferation of vascular
smooth muscle cells within small pulmonary arteries in this
disease (4) and exuberant expansions of endothelial cells in
plexiform lesions (38). Recent work by Launay et al. (39)
demonstrates potentiation of hypoxia-induced vascular pro-
liferation in mice that receive dexfenfluramine. These effects
appear to be mediated through 5-HT2B receptors because
both genetic and pharmacologic inhibition of this receptor
inhibits this response in mice. Humbert et al. (40) recently
demonstrated a significant increase in the incidence of
BMPR2 mutations in patients who developed PPH after
exposure to fenfluramine. More precise characterization of
pleoitropic factors that can induce inappropriate vascular
proliferative responses to injury may eventually lead to
effective anti-proliferative therapies for prevention and
treatment of PPH. To this end, experimental models of
PPH have been established in which rats develop neointi-
mal vascular occlusion, pulmonary arterial hypertension,
right ventricular hypertrophy, and death (41). The develop-
ment of disease in this model mimics both the pathophys-
iology and pathology of human disease, and furthermore,
the pulmonary hypertension can be attenuated by anti-
proliferative or pro-apoptotic compounds, such as rapamy-
cin (42) and simvastatin (43). The exciting implication is
that anti-proliferative compounds, rather than vasodilators,
may provide the new wave of therapies for patients with
PPH (44) and prevention of PPH in susceptible individuals
(45).
The current 12-month study of oral beraprost by Barst et
al. (27) demonstrates the challenge and importance of
performing clinical trials in PPH. Beraprost improved
exercise performance at three and six months but not at nine
and 12 months. Beraprost is likely to be producing its
modest effects through vasodilation rather than through
substantial anti-proliferative properties (21). This current
study provides important data on the natural history of
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PPH, both treated and untreated. The data reveal that, in
the absence of therapies directed at reversing the pathologic
process of pulmonary vascular occlusion, pulmonary hyper-
tension remains a progressive disease.
The recognition that vascular obliteration in PPH is
associated with genetic abnormalities in anti-proliferative
signaling suggests the importance of evaluating new thera-
pies directed at preventing pathological vascular prolifera-
tion in vivo. Future clinical trials in PPH should be designed
to identify those agents or combinations of agents that will
provide sustained efficacy combined with safety. Such ther-
apies will inhibit and reverse vascular occlusion and pulmo-
nary hypertension and extend survival. We should not be
complacent with therapies that provide short-term benefit;
rather, we should use these data as further impetus not only
to study the pathogenesis of PPH but also to search for a
cure.
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